Rapid Micro Biosystems (NASDAQ:RPID) executives highlighted the company’s effort to modernize microbial quality control in pharmaceutical manufacturing, discussed recent customer engagement activity, and outlined key variables behind its 2026 outlook during a Q&A session hosted by KeyBanc’s Anna Snopkowski. Automating a “mandatory regulated step” in pharmaceutical manufacturing CEO Rob Spignesi described microbial quality control as […]